Consult
Log In
Menu
Consult
Log in

PierianDx

Recent Posts by PierianDx:

by PierianDx, on August 11, 2020

Comprehensive genomic profiling is emerging as a powerful tool in our arsenal to treat cancer. It’s easy to see why: with a minimal amount of sample, clinicians are able to identify all four types of genetic alterations across a large set of genes with known relevance to cancer. When you consider that up to 90% of patients who undergo comprehensive genomic profiling may have an actionable genetic alteration1-6 , you begin to understand how this new diagnostic tool can revolutionize cancer care.  

Read Story
Topics:Blog

by PierianDx, on August 3, 2020

Next generation sequencing continues to gain traction as a standard of care as it becomes less complex and less costly. Targeted sequencing, in which only a subset of genes are enriched and amplified for sequencing, is especially cost effective. Clinicians are using the technique to more quickly provide answers to oncologists to ensure that patients actually get the right therapy. 

Read Story
Topics:Blog

by PierianDx, on June 25, 2020

What is the one thing we must do if we are to give complex disease a run for its money? According to Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman at PierianDx, we must amass and share patient data in a safe and compliant manner to answer complex questions more quickly. In this informational interview, Dr. Nagarajan sits down with VOL reporter, Daiva Sen, to discuss the importance of data sharing and other topics, including: 

  • Universal healthcare systems and the importance of accessibility
  • Genomic data sharing, regulation, and privacy
  • Real-world evidence in managing patient care

To learn more, watch the video.

Read Story
Topics:Blog

by PierianDx, on May 28, 2020

Precision medicine continues to gain traction, and increasingly, clinicians are turning to comprehensive genomic profiling to match the right drug to a patient using information about that patient’s genetic mutations.

Read Story
Topics:Blog

by PierianDx, on May 5, 2020

Collaboration will create integrated clinical interpretation and reporting solution

Read Story
Topics:News

by PierianDx, on March 18, 2020

Sequencing technology advances, such as comprehensive profiling assays, lower costs, and improved reimbursement continue to drive the adoption of clinical next generation sequencing. Organizations, such as Foundation Medicine, provide comprehensive NGS tests and resulting reports that physicians can order for patients with solid tumors. However, an increasing number of academic medical centers and healthcare organizations are opting to internalize their NGS testing program because it gives them greater control over tissue, turnaround time, and it provides more opportunity for interaction between ordering physicians and those running the tests. 

Arriving at the decision to build an internal NGS test menu is often the first hurdle for healthcare organizations. What comes next can be even more challenging.

Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman PierianDx, recently sat down with Joseph Anderson, MD, The Personalized Diagnostics Podcast, to discuss the advent of personalized medicine and what it will take to make clinical NGS a routine part of healthcare. In particular, Rakesh and Joe discuss:

  • How the industry is shifting to larger (50+ gene) panels
  • How to think about bringing a test online and addressing complex components, such as validation
  • How to address the variant interpretation bottleneck

To learn more, listen to the podcast.

Read Story
Topics:Blog

by PierianDx, on December 11, 2019

Intermountain Healthcare joins PierianDx’s partner network to accelerate precision medicine

Read Story
Topics:News

by PierianDx, on October 28, 2019

Funding led by ATW Partners and SJF Ventures with follow-on Investment from Health Catalyst Capital, RTI International, and Inova Health Systems

Read Story
Topics:News

by PierianDx, on March 20, 2019

PierianDx will be highlighting germline features of its genomics technology platform at the American College of Medical Genetics and Genomics (ACMG) annual meeting April 2-6 in Seattle, Washington. 

Read Story
Topics:Blog

by PierianDx, on February 26, 2019

Genomic tests that use next generation sequencing (NGS) technology are on the rise, and there’s a growing trend for hospitals to insource these tests to improve turnaround time and reduce costs. However, these tests can be challenging to implement. Challenges include lack of bioinformatics expertise, the cost and expense of deploying a new test, and reimbursement, to name a few.

Read Story
Topics:Blog

by PierianDx, on February 25, 2019

In just under 15 years, next generation sequencing (NGS) has evolved from a technology that only an exclusive few research laboratories had access to, to one in use by nearly 300 clinical laboratories worldwide.1,2

Read Story
Topics:Blog

by PierianDx, on February 7, 2019

At PierianDx, we are well-versed in helping healthcare organizations implement clinical next generation sequencing (NGS) testing programs. But beyond implementation of genomic testing programs at individual institutions, what must happen to make this technology more readily available to all? 

Read Story
Topics:Blog